| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/16/2009 | CA2702103A1 Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| 04/16/2009 | CA2702043A1 Compositions and methods for ribonuclease-based therapies |
| 04/16/2009 | CA2701932A1 Chiral cis-imidazolines |
| 04/16/2009 | CA2701868A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | CA2701865A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | CA2701626A1 Compounds from myrothecium sp. for inhibiting the growth of cancer cells |
| 04/16/2009 | CA2701525A1 Thiazole derivatives |
| 04/16/2009 | CA2701519A1 Piperidine and piperazine derivatives |
| 04/16/2009 | CA2701057A1 Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
| 04/16/2009 | CA2700893A1 Substituted tetrazole compounds and uses thereof |
| 04/16/2009 | CA2700795A1 Isoxazole compound for the treatment of cancer |
| 04/16/2009 | CA2699257A1 Cgrp as a therapeutic agent |
| 04/16/2009 | CA2699169A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | CA2699168A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | CA2699163A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699090A1 Combination therapy with antibody-drug conjugates |
| 04/16/2009 | CA2699088A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699084A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | CA2699083A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2696424A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 |
| 04/16/2009 | CA2696423A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
| 04/15/2009 | EP2048230A1 Cell death inducer |
| 04/15/2009 | EP2048228A2 Human liver progenitors |
| 04/15/2009 | EP2048163A1 Antihuman alpha- 9 integrin antibody and use of the same |
| 04/15/2009 | EP2048158A1 Glycosylated human alpha interferon muteins, method for obtaining them and use |
| 04/15/2009 | EP2048157A1 Polynucleotide encoding the rg1 polypeptide |
| 04/15/2009 | EP2048145A1 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| 04/15/2009 | EP2048142A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| 04/15/2009 | EP2047864A1 Use of rpn2 gene expression inhibitor |
| 04/15/2009 | EP2047858A1 Combination products for treating cancer |
| 04/15/2009 | EP2047855A1 Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) |
| 04/15/2009 | EP2047850A2 Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| 04/15/2009 | EP2047849A1 Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors |
| 04/15/2009 | EP2047271A1 Method for establishing the sensitivity of tumours to capecitabin and test kit |
| 04/15/2009 | EP2047256A1 A method for the in vitro screening of anti-cancer compounds that inhibits sk3 activity, and said anti-cancer compounds |
| 04/15/2009 | EP2046836A1 Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same |
| 04/15/2009 | EP2046834A1 Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
| 04/15/2009 | EP2046799A1 Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| 04/15/2009 | EP2046796A1 Tetrahydrofuro [3, 2 -b]pyrr0l-3-ones as cathepsin k inhibitors |
| 04/15/2009 | EP2046776A2 Methods and apparatus for identifying subject matter in view data |
| 04/15/2009 | EP2046764A1 Substituted isoxalines, pharmaceutical compositions containing same, methods of preparing same, and uses of same |
| 04/15/2009 | EP2046759A1 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| 04/15/2009 | EP2046758A1 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 04/15/2009 | EP2046740A1 Compounds having crth2 antagonist activity |
| 04/15/2009 | EP2046738A1 Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation |
| 04/15/2009 | EP2046737A2 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| 04/15/2009 | EP2046381A1 Cancerous disease modifying antibodies |
| 04/15/2009 | EP2046369A2 Recombinant host for producing l-asparaginase ii |
| 04/15/2009 | EP2046352A1 Fermented milk product and use thereof |
| 04/15/2009 | EP2046349A1 Treatment of excessive neovascularization |
| 04/15/2009 | EP2046333A2 Thiozolidinedione derivatives as p13 kinase inhibitors |
| 04/15/2009 | EP2046331A1 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
| 04/15/2009 | EP2046330A2 Pharmaceutical combinations |
| 04/15/2009 | EP2046326A2 Annellated pyrrole compounds for cancer management |
| 04/15/2009 | EP2046323A2 Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| 04/15/2009 | EP2046317A2 Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives |
| 04/15/2009 | EP2046315A2 Therapeutic agents for the treatment of lymphoid malignancies |
| 04/15/2009 | EP2046308A2 Retinoids and small molecules as nrf2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation |
| 04/15/2009 | EP2003130A9 Novel pyridine derivative having anti-helicobacter pylori activity |
| 04/15/2009 | EP2002840A9 Method for treating oncological diseases |
| 04/15/2009 | EP1809630B1 4-amino-5-oxo-8-phenyl-5h-pyrido-[2,3-d]-pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours |
| 04/15/2009 | EP1797881B1 Medicinal composition with improved stability and reduced gelation properties |
| 04/15/2009 | EP1794148B1 Novel phthalazinone derivatives, as aurora-a kinase inhibitors |
| 04/15/2009 | EP1720994B1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same |
| 04/15/2009 | EP1686997B1 Inhibitors of the mutant form of kit |
| 04/15/2009 | EP1572686B1 Anthranilic acid amide derivatives and their pharmaceutical use |
| 04/15/2009 | EP1478360B1 Agents which interact with a serotonin transporter for the treatment of cancer |
| 04/15/2009 | EP1423115B1 Antiangiogenic activity of nitrogen substituted thalidomide analogs |
| 04/15/2009 | EP1419143B1 24-sulfur-substituted analogs of 1alpha,25-dihydroxy vitamin d3 |
| 04/15/2009 | EP1417307B1 Oligonucleotide compositions and their use to induce apoptosis |
| 04/15/2009 | EP1385547B1 Antibody which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 04/15/2009 | EP1363635B1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 04/15/2009 | EP1311532B1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 04/15/2009 | EP1267882B1 Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis |
| 04/15/2009 | EP1257295B1 Factor vii or viia-like molecules |
| 04/15/2009 | EP1244648B1 Chemokine receptor binding heterocyclic compounds |
| 04/15/2009 | EP1203007B1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) and its receptor c-met |
| 04/15/2009 | EP1156835B1 Method for radiolabeling proteins with yttrium-90 |
| 04/15/2009 | EP1012267B1 An antisense oligonucleotide preparation method |
| 04/15/2009 | EP0792292B2 Estrogen receptor |
| 04/15/2009 | CN101410413A Anti-EPHRINB2 antiboies and methods using same |
| 04/15/2009 | CN101410391A 2, 3-phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 04/15/2009 | CN101410388A Compounds for the treatment of inflammatory disorders |
| 04/15/2009 | CN101410367A Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| 04/15/2009 | CN101410137A Anti-IGF-1R human monoclonal antibody formulation |
| 04/15/2009 | CN101410114A A3 adenosine receptor allosteric modulators |
| 04/15/2009 | CN101410108A Use of a kinase inhibitor for the treatment of particular resistant tumors |
| 04/15/2009 | CN101407815A Preparing method of glycine-N-methyltransferase (GNMT) knockout mouse model and use thereof |
| 04/15/2009 | CN101407812A Heterologous expression and purification method for human RANTES protein having chemotaxis |
| 04/15/2009 | CN101407810A Small interfering RNA with midkine gene as target, vector and use thereof |
| 04/15/2009 | CN101407743A Method for extracting and separating curcuma oil |
| 04/15/2009 | CN101407558A Preparation of Dendrobium nobile polysaccharide extract and use there |
| 04/15/2009 | CN101407557A Preparation and use of Dendrobium nobile polysaccharide extract |
| 04/15/2009 | CN101407556A Preparation of Cordyceps sinensis polysaccharide injection and use in cancer treatment |
| 04/15/2009 | CN101407545A 131I labeled anti-tumor humanized monoclonal antibody 1E2 and use thereof |
| 04/15/2009 | CN101407539A Oligopeptide having marrow hemopoiesis protection function, preparation thereof, pharmaceutical composition containing the oligopeptide and use |
| 04/15/2009 | CN101407524A Oxazino camptothecin derivative, preparation and use thereof |
| 04/15/2009 | CN101407523A Myrothecium mycelium extract for inhibiting growth of tumour cell |
| 04/15/2009 | CN101407516A Camptothecine derivative having anticancer activity |
| 04/15/2009 | CN101407515A Chinoline polycyclic compounds as CDK inhibitors |